Lymphomatoid Papulosis 

  • Author: John A Zic; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 24, 2012
 

Background

Lymphomatoid papulosis (LyP) is a chronic papulonecrotic or papulonodular skin disease with histologic features suggestive of a malignant lymphoma. The disease is characterized by recurrent crops of pruritic papules at different stages of development that predominantly arise on the trunk and limbs. The papules heal spontaneously over 1-2 months, usually leaving slightly depressed oval scars.

The term lymphomatoid papulosis originally was used by Macaulay[1] in 1968 to describe "a self-healing rhythmical paradoxical eruption, histologically malignant but clinically benign." Due to the typical waxing and waning clinical course, lymphomatoid papulosis was previously considered a pseuodolymphomatous inflammatory process. However, the classification system for cutaneous lymphomas has evolved rapidly, and, during consensus meetings in 2003-2004, the World Health Organization—European Organization for Research and Treatment of Cancer (WHO-EORTC) classification grouped lymphomatoid papulosis among the indolent cutaneous T-cell lymphomas. The rationale for classifying lymphomatoid papulosis as a cutaneous lymphoma is its association with other malignant lymphoproliferative disorders; however, some experts hesitate to classify this chronic skin disease as a true malignancy because of its spontaneous resolution and benign clinical course.[2, 3, 4, 5]

Lymphomatoid papulosis is part of a spectrum of CD30 (Ki-1)–positive cutaneous lymphoproliferative diseases (CD30+ LPDs), including lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline CD30+ lesions. Also see Cutaneous CD30+ (Ki-1) Anaplastic Large-Cell Lymphoma.

Also see the eMedicine articles Malignant Melanoma (dermatology focus), Malignant Melanoma (oncology focus), Cutaneous T-Cell Lymphoma, and Lymphoma, Cutaneous T-Cell.

Next

Pathophysiology

The CD30 antigen is a type 1 transmembrane glycoprotein of the tumor necrosis factor receptor superfamily. In addition to the CD30+ lymphoproliferative diseases, malignant lymphomas such as Hodgkin disease (HD), node-based systemic anaplastic large cell lymphoma (ALCL), and mycosis fungoides (MF) with large cell transformation may express the CD30 antigen.

The pathophysiology of CD30+ LPDs, including lymphomatoid papulosis (LyP), is largely unknown. CD30 signaling is known to have an effect on the growth and survival of lymphoid cells, and one hypothesis is that genetic instability and accumulated genetic defects may have a role in the development of lymphomatoid papulosis and the progression to associated neoplasms. In a recent study, the 30M377 allelic form of the CD30 promoter microsatellite repressive element was associated with the development of lymphomatoid papulosis, and the 30M362 allelic form was associated with progression to other CD30+ lymphomas in lymphomatoid papulosis patients.

Genetic instability of tumor cells may lead to altered expression of apoptotic proteins and immune-regulatory molecules, such as transforming growth factor-beta. Other research has found overexpression of JunB,[6] part of the AP-1 transcription factor complex involved in cell proliferation and apoptosis, in virtually all CD30+ lymphomas. Consequently, JunB is a potential target for experimental therapy in patients with these tumors.

Spontaneous regression of lymphomatoid papulosis is seen almost universally, whereas regression occurs in approximately 25% of pcALCL cases. Therefore, the higher apoptotic index found in lymphomatoid papulosis compared with pcALCL is not surprising. The proapoptotic protein Bax is also expressed at high levels in CD30+ cutaneous lymphoproliferative diseases and may play a crucial role in mediating apoptosis of tumor cells. Another recent study suggested that the death-receptor apoptosis pathway mediated by Fas-associating protein with death domain (FADD) may be responsible for the varying biologic behaviors of CD30+ LPDs involving the skin.[7]

Previous
Next

Epidemiology

Frequency

United States

The prevalence of lymphomatoid papulosis is estimated to be 1.2-1.9 cases per million population. The CD30+ cutaneous lymphoproliferative disorders account for approximately 25% of cutaneous T-cell lymphoma cases.

Mortality/Morbidity

Lymphomatoid papulosis has a chronic, indolent course in most patients; however, estimates indicate that as many as 10-20% of lymphomatoid papulosis patients have a history of associated malignant lymphoma (ALCL, HD, or MF) prior to, concurrent with, or subsequent to the diagnosis of lymphomatoid papulosis. In a recent longitudinal study, no patients with lymphomatoid papulosis died of the disease.

pcALCL is more likely than MF to manifest as an ulcerated tumor and palpable lymph nodes. MF is the most common variant of cutaneous T-cell lymphoma and is characterized by the development of red patches or plaques in sun-protected areas. MF is more likely to manifest as patches and plaques than tumors. Disease-specific survival at 5 and 10 years for pcALCL was 85% in a recent study.

Associated lymphomas more rarely include immunoblastic lymphoma, lethal midline granuloma (currently considered as natural killer cell lymphoma in many patients), and systemic lymphocytic lymphoma. In most patients, the malignancy develops many years after the diagnosis of lymphomatoid papulosis.

Race

Black persons may be less affected by lymphomatoid papulosis than persons of other racial groups.

Sex

No consistent sex predominance is found in studies of lymphomatoid papulosis, but some studies have reported a male-to-female ratio of 1.5-2:1.

Age

Lymphomatoid papulosis may develop at any age, but the peak incidence occurs in the fifth decade.

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

John A Zic  MD, Associate Professor of Medicine/Dermatology, Director, VU Cutaneous Lymphoma Clinic, Vanderbilt University School of Medicine

John A Zic is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Gregory J Raugi, MD, PhD  Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle School of Medicine; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle

Gregory J Raugi, MD, PhD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Daniel S Loo, MD  Associate Professor of Dermatology, Residency Program Director, Department of Dermatology, Tufts Medical Center

Daniel S Loo, MD is a member of the following medical societies: American Academy of Dermatology and Association of Professors of Dermatology

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous Chief Editor, William D. James, MD, and previous author, Kristina Collins, MD, to the development and writing of this article.

References

  1. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol. Jan 1968;97(1):23-30. [Medline].

  2. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. Nov 2005;153(5):874-80. [Medline].

  3. Willemze R, Meijer CJ. Classification of cutaneous T-cell lymphoma: from Alibert to WHO-EORTC. J Cutan Pathol. Feb 2006;33 Suppl 1:18-26. [Medline].

  4. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. May 15 2005;105(10):3768-85. [Medline].

  5. de Souza A, El-Azhary RA, Camilleri MJ, Wada DA, Appert DL, Gibson LE. In search of prognostic indicators for lymphomatoid papulosis: A retrospective study of 123 patients. J Am Acad Dermatol. Oct 7 2011;[Medline].

  6. Rassidakis GZ, Thomaides A, Atwell C, et al. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol. Oct 2005;18(10):1365-70. [Medline].

  7. Clarke LE, Bayerl MG, Bruggeman RD, et al. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Am J Surg Pathol. Apr 2005;29(4):452-9. [Medline].

  8. Pujol RM, Muret MP, Bergua P, Bordes R, Alomar A. Oral involvement in lymphomatoid papulosis. Report of two cases and review of the literature. Dermatology. 2005;210(1):53-7. [Medline].

  9. de-Misa RF, Garcia M, Dorta S, et al. Solitary oral ulceration as the first appearance of lymphomatoid papulosis: a diagnostic challenge. Clin Exp Dermatol. May 21 2009;[Medline].

  10. Wang HH, Lach L, Kadin ME. Epidemiology of lymphomatoid papulosis. Cancer. Dec 15 1992;70(12):2951-7. [Medline].

  11. Moura FN, Thomas L, Balme B, Dalle S. Dermoscopy of lymphomatoid papulosis. Arch Dermatol. Aug 2009;145(8):966-7. [Medline].

  12. Kim YC, Yang WI, Lee MG, et al. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. Int J Dermatol. Nov 2006;45(11):1312-6. [Medline].

  13. Vonderheid EC, Kadin ME, Gocke CD. Lymphomatoid papulosis followed by pityriasis lichenoides: a common pathogenesis?. Am J Dermatopathol. Dec 2011;33(8):835-40. [Medline].

  14. Leo AM, Ermolovich T. Lymphomatoid papulosis while on efalizumab. J Am Acad Dermatol. Sep 2009;61(3):540-1. [Medline].

  15. Talsania N, O'Toole EA. Severe hypersensitivity reaction to minocycline in association with lymphomatoid papulosis. Clin Exp Dermatol. Oct 2009;34(7):e397-8. [Medline].

  16. KIM SK, KIM YC. Lymphomatoid papulosis after allogenic stem cell transplantation. Eur J Dermatol. Sep-Oct 2009;19(5):520-1. [Medline].

  17. de Souza A, Gibson LE, Wada DA, et al. Resolution of CD8+ lymphomatoid papulosis after surgical excision of the type AB-thymoma. Am J Dermatopathol. Jul 2009;31(5):475-9. [Medline].

  18. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol. Apr 2004;140(4):441-7. [Medline].

  19. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. Jun 1993;28(6):973-80. [Medline].

  20. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. Dec 2003;49(6):1049-58. [Medline].

  21. Bergstrom JS, Jaworsky C. Topical methotrexate for lymphomatoid papulosis. J Am Acad Dermatol. Nov 2003;49(5):937-9. [Medline].

  22. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. Mar 1996;34(3):470-81. [Medline].

  23. Jain N, Gutte R, Jadhav P, Khopkar U. Granulomatous and eccrinotropic lymphomatoid papulosis. Indian J Dermatol Venereol Leprol. Jan 2012;78(1):82-4. [Medline].

  24. Yip L, Darling S, Orchard D. Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate. Australas J Dermatol. Nov 2011;52(4):279-83. [Medline].

  25. Hoetzenecker W, Guenova E, Hoetzenecker K, Yazdi A, Röcken M, Berneburg M. Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. Eur J Dermatol. Nov-Dec 2009;19(6):646-7. [Medline].

  26. Hughes PS. Treatment of lymphomatoid papulosis with imiquimod 5% cream. J Am Acad Dermatol. Mar 2006;54(3):546-7. [Medline].

  27. Kontos AP, Kerr HA, Malick F, Fivenson DP, Lim HW, Wong HK. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoimmunol Photomed. Jun 2006;22(3):168-71. [Medline].

  28. Rodrigues M, McCormack C, Yap LM, et al. Successful treatment of lymphomatoid papulosis with photodynamic therapy. Australas J Dermatol. May 2009;50(2):129-32. [Medline].

  29. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. Jun 1992;126(6):596-602. [Medline].

  30. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol. May 2002;29(5):295-300. [Medline].

  31. Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med. Feb 1 1995;122(3):210-7. [Medline].

  32. Demierre MF, Goldberg LJ, Kadin ME, Koh HK. Is it lymphoma or lymphomatoid papulosis?. J Am Acad Dermatol. May 1997;36(5 Pt 1):765-72.

  33. el-Azhary RA, Gibson LE, Kurtin PJ, Pittelkow MR, Muller SA. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J Am Acad Dermatol. Feb 1994;30(2 Pt 1):210-8. [Medline].

  34. Flann S, Orchard GE, Wain EM, Russell-Jones R. Three cases of lymphomatoid papulosis with a CD56+ immunophenotype. J Am Acad Dermatol. Nov 2006;55(5):903-6. [Medline].

  35. Franchina M, Kadin ME, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev. May 2005;14(5):1322-5. [Medline].

  36. Gellrich S, Wernicke M, Wilks A, et al. The cell infiltrate in lymphomatoid papulosis comprises a mixture of polyclonal large atypical cells (CD30-positive) and smaller monoclonal T cells (CD30-negative). J Invest Dermatol. Mar 2004;122(3):859-61. [Medline].

  37. Greisser J, Doebbeling U, Roos M, et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol. May 2005;14(5):380-5. [Medline].

  38. Gruber R, Sepp NT, Fritsch PO, Schmuth M. Prognosis of lymphomatoid papulosis. Oncologist. Sep 2006;11(8):955-7; author reply 957. [Medline].

  39. Kadin ME. Pathobiology of CD30+ cutaneous T-cell lymphomas. J Cutan Pathol. Feb 2006;33 Suppl 1:10-7. [Medline].

  40. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol. Feb 2006;33 Suppl 1:58-70. [Medline].

  41. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. Dec 2003;49(6):1049-58. [Medline].

  42. Magro CM, Crowson AN, Morrison C, Merati K, Porcu P, Wright ED. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol. Apr 2006;125(4):490-501. [Medline].

  43. Schultz JC, Granados S, Vonderheid EC, Hwang ST. T-cell clonality of peripheral blood lymphocytes in patients with lymphomatoid papulosis. J Am Acad Dermatol. Jul 2005;53(1):152-5. [Medline].

  44. Wang HH, Lach L, Kadin ME. Epidemiology of lymphomatoid papulosis. Cancer. Dec 15 1992;70(12):2951-7. [Medline].

  45. Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. Jul 1995;105(1):51-5. [Medline].

  46. Yagi H, Seo N, Ohshima A, et al. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. Am J Surg Pathol. Sep 2006;30(9):1111-9. [Medline].

  47. Yamaguchi T, Ohshima K, Karube K, et al. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol. May 2006;154(5):904-9. [Medline].

 
Previous
Next
 
Lymphomatoid papulosis type C on the upper back of a 65-year-old woman with waxing and waning papulonodular eruptions for almost 10 years. The eruption was suppressed completely using methotrexate.
Crusted ulcerated papule of lymphomatoid papulosis on the left hip of a 47-year-old woman with a longer than 20-year history of recurrent papulonodular eruption with spontaneous resolution.
Large indurated plaques of anaplastic large cell lymphoma of 2-months' duration on the left lateral thigh of a 57-year-old man with a 5-year history of lymphomatoid papulosis. The lymphomatoid papulosis skin lesions (not pictured) were rarely larger than 6 mm.
Lymphomatoid papulosis type A showing a cluster of pink papules and 2 crusted papules that resolved spontaneously in the left axilla of a 68-year-old man. The first symptoms developed in the popliteal fossa 8 years before erupting into more widespread papules 10 months before this photograph was taken.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.